Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tilray Brands, Inc. (TLRY.TO)
Leamington, ON, CA
Tilray Brands, Inc. operates as a global enterprise deeply involved in the entire lifecycle of cannabis products, from initial research and cultivation to manufacturing, marketing, and distribution. Its reach extends across a multitude of international markets, including Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company's diverse operations are segmented into four key areas: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. Within its portfolio, Tilray provides a broad spectrum of medical and adult-use cannabis offerings, such as GMP-certified flowers, oils, vapes, edibles, and topicals. Beyond cannabis, the company also procures and resells various pharmaceutical and wellness products. Furthermore, Tilray is active in the production, promotion, and distribution of alcoholic beverages, alongside hemp-based food items and other wellness-focused goods. These numerous products are marketed under a wide array of brands, including Tilray, Aphria, Broken Coast, SweetWater, Breckenridge Distillery, and others. The company’s sales channels are extensive, serving retailers, wholesalers, individual patients, physicians, hospitals, pharmacies, researchers, government entities, and direct-to-consumer markets. Previously named Tilray, Inc., the corporation's main headquarters are situated in Leamington, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.45% | +2.43% | -10.51% | -29.36% | -34.09% | -38.92% | +37.82% | -66.31% | -96.31% | -96.08% | -96.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 7 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.1% Q1'26: +11.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-630.3% Q1'26: +97.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-261.0% Q1'26: -12.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-275.3% Q1'26: -8.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-144.8% Q1'26: -4.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+22.3% Q1'26: +24.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.15× Q1'26: -51.04× (vs Q1'25)
| Metric |
May 2019 actual |
May 2020 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 9 Rev. Ana. 2 EPS Ana. |
May 2027 9 Rev. Ana. 7 EPS Ana. |
May 2028 3 Rev. Ana. 5 EPS Ana. |
May 2029 4 Rev. Ana. 2 EPS Ana. |
May 2030 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
175.25M
est: 42.26M (+314.6%)
|
391.00M
est: 165.12M (+136.8%)
|
513.09M
est: 207.95M (+146.7%)
|
628.37M
est: 631.66M (-0.5%)
|
627.12M
est: 602.01M (+4.2%)
|
788.94M
est: 784.96M (+0.5%)
|
821.31M
est: 831.23M (-1.2%)
|
886.39M
860.39M – 920.63M
+6.6% YoY
|
1.10B
949.91M – 1.18B
+24.6% YoY
|
1.17B
1.07B – 1.24B
+6.2% YoY
|
1.22B
1.11B – 1.29B
+4.0% YoY
|
1.31B
1.19B – 1.38B
+7.2% YoY
|
| EBITDA |
-36.66M
est: -24.60M (-49.0%)
|
-18.40M
est: -96.10M (+80.9%)
|
-218.36M
est: -121.03M (-80.4%)
|
-246.40M
est: -367.63M (+33.0%)
|
-1.27B
est: -350.38M (-263.4%)
|
-72.84M
est: -456.85M (+84.1%)
|
-2.13B
est: -483.78M (-339.8%)
|
-515.88M
-535.82M – -500.75M
-6.6% YoY
|
-642.63M
-688.85M – -552.86M
-24.6% YoY
|
-682.73M
-721.72M – -620.91M
-6.2% YoY
|
-709.89M
-750.43M – -645.61M
-4.0% YoY
|
-760.76M
-804.20M – -691.87M
-7.2% YoY
|
| EBIT |
-32.26M
est: -28.09M (-14.8%)
|
-83.54M
est: -109.73M (+23.9%)
|
-314.08M
est: -138.20M (-127.3%)
|
-400.99M
est: -419.78M (+4.5%)
|
-1.40B
est: -400.08M (-250.8%)
|
-199.76M
est: -521.66M (+61.7%)
|
-2.26B
est: -552.41M (-309.3%)
|
-589.07M
-611.83M – -571.79M
-6.6% YoY
|
-733.79M
-786.58M – -631.29M
-24.6% YoY
|
-779.59M
-824.11M – -709.00M
-6.2% YoY
|
-810.60M
-856.89M – -737.20M
-4.0% YoY
|
-868.68M
-918.29M – -790.02M
-7.2% YoY
|
| Net Income |
-12.19M
est: -525.07M (+97.7%)
|
-61.02M
est: -1.21B (+95.0%)
|
-336.01M
est: -2.21B (+84.8%)
|
-434.13M
est: -69.68M (-523.1%)
|
-1.44B
est: -2.03B (+29.0%)
|
-244.98M
est: -281.22M (+12.9%)
|
-2.19B
est: -1.08B (-103.3%)
|
-56.03M
-338.68M – 226.63M
+94.8% YoY
|
-30.26M
-73.64M – -4.55M
+46.0% YoY
|
5.46M
4.82M – 5.87M
+118.1% YoY
|
40.98M
36.15M – 44.02M
+650.0% YoY
|
75.58M
66.68M – 81.19M
+84.4% YoY
|
| SGA |
91.50M
est: 14.11M (+548.5%)
|
118.22M
est: 55.13M (+114.5%)
|
155.69M
est: 69.43M (+124.2%)
|
228.66M
est: 210.89M (+8.4%)
|
230.94M
est: 200.99M (+14.9%)
|
250.72M
est: 262.07M (-4.3%)
|
259.48M
est: 277.52M (-6.5%)
|
295.93M
287.25M – 307.37M
+6.6% YoY
|
368.64M
317.14M – 395.15M
+24.6% YoY
|
391.64M
356.18M – 414.01M
+6.2% YoY
|
407.22M
370.35M – 430.48M
+4.0% YoY
|
436.40M
396.89M – 461.32M
+7.2% YoY
|
| EPS |
-0.60
est: -5.78 (+89.6%)
|
-2.70
est: -13.35 (+79.8%)
|
-12.50
est: -24.28 (+48.5%)
|
-9.00
est: -0.77 (-1,073.3%)
|
-23.40
est: -22.36 (-4.6%)
|
-3.30
est: -3.10 (-6.6%)
|
-24.10
est: -11.84 (-103.5%)
|
-0.62
-3.73 – 2.49
+94.8% YoY
|
-0.33
-0.81 – -0.05
+46.0% YoY
|
0.06
0.05 – 0.06
+118.1% YoY
|
0.45
0.40 – 0.48
+650.0% YoY
|
0.83
0.73 – 0.89
+84.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 264.3K | 0.40% |
| 2 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 12.6K | 0.09% |
| 3 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 205.7K | 0.03% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Irwin David Simon | President, Chief Executive Officer & Chairman | 8M | male |
| Denise Menikheim Faltischek | Chief Strategy Officer and Head of M&A | 2M | female |
| Mitchell S. Gendel | Global General Counsel & Corporate Secretary | 2M | male |
| Carl A. Merton | Chief Financial Officer & Principal Accounting Officer | 1M | male |
| Roger Savell | Chief Administrative Officer & Chief Financial Officer of International | 1M | male |
| Rajnish Ohri | President of International | — | male |
| Jared Simon | President of Manitoba Harvest & Tilray Wellness | — | male |
| Blair MacNeil | President of Tilray Canada | — | male |
| Berrin Noorata | Chief Corporate Affairs Officer | — | female |
| Lloyd Brathwaite | Chief Information Officer | — | male |
| Nyree Pinto | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TLRY.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
